| Basics |
MacroGenics, Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company. It focusses on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases.
|
| IPO Date: |
October 10, 2013 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$93.69M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.50 | 3.04%
|
| Avg Daily Range (30 D): |
$0.07 | 4.39%
|
| Avg Daily Range (90 D): |
$0.08 | 4.02%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
.54M |
| Avg Daily Volume (30 D): |
.45M |
| Avg Daily Volume (90 D): |
.61M |
| Trade Size |
| Avg Trade Size (Sh.): |
106 |
| Avg Trade Size (Sh.) (30 D): |
130 |
| Avg Trade Size (Sh.) (90 D): |
142 |
| Institutional Trades |
| Total Inst.Trades: |
2,250 |
| Avg Inst. Trade: |
$1.68M |
| Avg Inst. Trade (30 D): |
$1M |
| Avg Inst. Trade (90 D): |
$1M |
| Avg Inst. Trade Volume: |
.1M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.73M |
| Avg Closing Trade (30 D): |
$1M |
| Avg Closing Trade (90 D): |
$1M |
| Avg Closing Volume: |
107.5K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$-.89
|
$-.65
|
$-.25
|
|
Diluted EPS
|
$-.89
|
$-.65
|
$-.25
|
|
Revenue
|
$ 154.05M
|
$ 13.19M
|
$ 19.35M
|
|
Gross Profit
|
$
|
$
|
$ 19.12M
|
|
Net Income / Loss
|
$ -55.81M
|
$ -41.04M
|
$ -15.42M
|
|
Operating Income / Loss
|
$ -99.45M
|
$ -42.62M
|
$ -52.84M
|
|
Cost of Revenue
|
$ .58M
|
$ M
|
$ .23M
|
|
Net Cash Flow
|
$ 65.22M
|
$ -37.27M
|
$ 3.22M
|
|
PE Ratio
|
|
|
|
|
